• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

RIP Bold AGN...


<























Bye Allergan...it was fun while it lasted. Those employees that lost their Allergan careers early on have to the the luckiest people on the face of the Earth because their anguish is no more...
 




Similar threads